Identify women with a genomically High 2 Risk of recurrence that clinical studies have demonstrated as having a significantly higher rate of pCR when treated neoadjuvantly.
Identify women with a genomically High 2 Risk of recurrence that clinical studies have demonstrated as having a significantly higher rate of pCR when treated neoadjuvantly.
Combining MammaPrint with BluePrint increases precision in determining Pathological Response and pCR within MammaPrint High Risk Tumors
Combining MammaPrint with BluePrint increases precision in determining Pathological Response and pCR within MammaPrint High Risk Tumors
- Patients with MammaPrint High 2 tumors, including Luminal B and Basal subtypes, are more likely to have PR or pCR with NCT, compared to Low Risk and High 1 patients
- These data suggest that MammaPrint High 2 identifies HR+HER2- cancers with higher sensitivity to NCT, which may enable downstaging and may improve overall outcomes
- There were no significant differences in the pCR rates between node negative and positive disease
- Menopausal status, T stage, nodal status, grade, and chemotherapy regimen did not significantly predict for PR or pC
Dive deeper into the data with our Medical team
Request Data Review / Additional Data:
